Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptomic changes after CDK12/13 inhibition by SR-4835 in ovarian cancer cell lines

ABSTRACT: CDK12/13 are transcriptional cyclin-dependent kinases shown to phosphorylate the C-terminal domain of RNA polymerase II. Here, we investigated the changes on the transcriptome level after inhibition of CDK12/13 by the specific inhibitor SR-4835 in a panel of ovarian cancer cell lines: SK-OV-3, A2780, A2780 cis, Caov-3, Caov-3 cis. All cell lines were treated for 24h with 90 nM SR-4835 prior RNA extraction and paired-end RNA sequencing. Differential gene expression, Ingenuity pathway analysis and genes with alternative exon usage was determined.

INSTRUMENT(S): Illumina NovaSeq 6000

ORGANISM(S): Homo sapiens

SUBMITTER: Frédéric Santer

PROVIDER: E-MTAB-15987 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

Transcriptomic data of inhibition of CDK12 in GBM12 cell line by SR-4835 treatment

Project description:This dataset contains transcriptomic profiles of the human glioblastoma cell line GBM12 following treatment with SR-4835, a selective CDK12 inhibitor. GBM12 cells were treated with SR-4835 or vehicle control for 24 hours, and total RNA was extracted for RNA sequencing. The study aims to elucidate transcriptional changes associated with CDK12 inhibition in glioblastoma and to identify downstream targets or pathways affected by SR-4835.

2025-08-29 | GSE306109 | GEO

SR-4835 in ovarian cancer

Project description:Transcriptomic changes after CDK12/13 inhibition by SR-4835 in ovarian cancer cell lines

| PRJEB93935 | ENA

CDK12/13 inhibition in NSCLC cell lines with acquired resistance to sotorasib

Project description:The efficacy of KRAS-G12C inhibitors in lung cancer is limited by the rapid onset of acquired resistance. While divergent mechanisms of resistance across patients and preclinical models have complicated efforts to identify therapeutic strategies for sotorasib-resistant cancers, we found that sotorasib-resistant H358 and LU65 cell lines, which have distinct mechanisms of resistance and drug sensitivity profiles, both exhibited increased vulnerability to treatment with SR-4835, an inhibitor of the transcriptional kinases CDK12 and CDK13. To identify CDK12/13-dependent genes linked to the increased sensitivity we observed in sotorasib-resistant over parental cells, we treated parental and sotorasib-resistant H358 and LU65 cells with SR-4835 and performed RNA sequencing.

2025-10-07 | GSE288707 | GEO

Stable CDK12 knock-out ovarian cancer cells do not show an increased sensitivity to cisplatin and PARP inhibitor treatment

Project description:We stabily knock-out CDK12 in A2780 cell line and performed RNA-Seq profiling comparing WT and KO conditions.

2022-07-11 | GSE183041 | GEO

Genome-wide Analysis Reveals SR Protein Cooperation and Competition in Regulated Splicing

Project description:SR proteins are well-characterized RNA binding proteins that promote exon inclusion by binding to exonic splicing enhancers (ESEs). However, it has been unclear whether regulatory rules deduced on model genes apply generally to activities of SR proteins in the cell. Here, we report global analyses of two prototypical SR proteins SRSF1 (SF2/ASF) and SRSF2 (SC35) using splicing-sensitive arrays and CLIP-seq on mouse embryo fibroblasts (MEFs). Unexpectedly, we find that these SR proteins promote both inclusion and skipping of exons in vivo, but their binding patterns do not explain such opposite responses. Further analyses reveal that loss of one SR protein is accompanied by coordinated loss or compensatory gain in the interaction of other SR proteins at the affected exons. Therefore, specific effects on regulated splicing by one SR protein actually depend on a complex set of relationships with multiple other SR proteins in mammalian genomes. SRSF1 and SRSF2 CLIP-seq

2013-04-05 | E-GEOD-44591 | biostudies-arrayexpress

RNA-seq analysis of the eight Drosophila SR protein family members

Project description:Using RNA-seq, we characterize the global AS regulation of the eight Drosophila SR protein family members RNA-seq experiments on two replicate samples from 8 individual SR protein knockdown (exptGroup=S), two replicates of simultaneous SR protein knockdown (XL6:B52 & SC35:B52) (exptGroup=D). Each exptGroup includes duplicate of its own non-specific (NS) controls.

2014-11-23 | E-GEOD-63263 | biostudies-arrayexpress

Expression data from RH30 IκBα SR cells and RH30 IkBa SR MyoD Crispr cells

Project description:Classical NF-κB activity can be inhibited by overexpression of the IκBα super repressor (SR). To determine the role of MyoD in rhabdomyosarcoma cells with NF-kB inhibited, ablated MyoD expression with CRISPR/cas9 editing and clonal selection of RH30-SR cell lines to compare differences in expression following deletion

2025-07-28 | GSE224171 | GEO

CDK10 suppression sensitizes cells to CDK12/13 blockade

Project description:A CRISPR screen with a CDK12/13 inhibitor identified CDK10 as a modulator of CDK12/13 blockade. CDK10 KO cells in OVCA and BRCA showed higher sensitivity to CDK12/13 inhibitors and increased apoptosis, compared to wild type cells. To investigate the effects on transcription, CDK10 KO cells with or without CDK12/13 inhibitor treatment were analyzed by RNA-sequencing.

2026-06-09 | GSE307213 | GEO

Discovery and design of molecular glue enhancers of CDK12-DDB1 interactions for targeted degradation of cyclin K

Project description:The CDK12 inhibitor, SR-4835, promotes the proteasomal degradation of cyclin K, contingent on the presence of CDK12 and the CUL4-RBX1-DDB1 E3 ligase complex. The inhibitor displays molecular glue activity, which correlates with its enhanced ability to inhibit cell growth. This effect is achieved by facilitating the formation of a ternary complex that requires the small molecule SR-4835, CDK12, and the adaptor protein DDB1, leading to the subsequent ubiquitination and degradation of cyclin K. We have successfully solved the structure of the ternary complex, enabling the de novo design of molecular glues that transform four different CDK12 scaffold inhibitors, including the clinical pan-CDK inhibitor dinaciclib, into cyclin K degraders. These results not only deepen our understanding of CDK12's role in cell regulation but also underscore significant progress in designing molecular glues for targeted protein degradation, paving the way for more precise and effective therapeutic strategies in cancer treatment.

2025-05-07 | PXD053505 | Pride

Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibition [nascent]

Project description:Cyclin-dependent kinases 12 and 13 (CDK12 and CDK13) play pivotal roles in orchestrating transcription elongation, DNA damage response, and maintenance of genomic stability. Aberrant CDK12 expression, homozygous loss, and mutations have been documented in various malignancies. Previous studies have demonstrated CDK12 and 13 are promising therapeutic targets in cancer. In this study, we developed a selective CDK12/13 PROTAC degrader YJ9069, which in a panel of cancer cell lines, affirm its effectiveness in inhibiting cell proliferation in subsets of cancer. CDK12/13 degradation rapidly triggers gene-length dependent transcriptional elongation defects, leading to DNA damage and cell cycle arrest. In vivo, YJ9069 significantly suppresses tumor growth in prostate cancer cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) models. Modifications of YJ9069 yielded a first-in-class orally bioavailable CDK12/13 degrader, YJ1206, which exhibits a comparable efficacy with significantly less toxicity. To identify pathways that may be synthetically lethal upon CDK12/13 degradation, we screened phosphorylation pathway arrays employing cell lines treated with YJ1206. Interestingly, degradation or genetic knock-down of CDK12/13, led to activation of the Akt pathway. Degradation of CDK12/13 with YJ1206, combined with AKT pathway inhibition with uprosertib, led to a striking synthetic lethal effect in pre-clinical models of prostate cancer. Taken together, these studies demonstrate that combination CDK12/13 and AKT pathway antagonism induces drug-drug synthetic lethality.

2024-08-14 | GSE262120 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data